Part 1 - General description of the company's activities and impact Clinically Vulnerable Families CIC was incorporated on 16 October 2024 to benefit Clinically Vulnerable people and the households they live with, across all four nations of the United Kingdom. “Clinically Vulnerable” refers to individuals identified in the COVID-19 Green Book as being at increased risk from infectious disease because of a health condition or age, together with the families and households who live with and support them. During the period 16 October 2024 to 31 October 2025, the company's activities benefited this community as follows: Representing the community's experience through the UK Covid-19 Inquiry. The company acted as a Core Participant in four modules of the UK Covid-19 Inquiry (Modules 3, 4, 8 and 10) and contributed evidence to four further modules. It gathered data and first-hand accounts from Clinically Vulnerable people and prepared organisational and oral witness evidence on their behalf alongside the questioning of key witnesses, ensuring the experiences of this community were placed before the Inquiry. Module 3 oral evidence concluded on 28 November 2024; Module 4 oral evidence hearings opened on 16 January 2025; and CVF also gave oral evidence for the company to Module 8 on 1 October 2025. This gave a voice to a community whose experiences might otherwise have gone unheard within an official process of national importance. Raising public awareness and understanding. The company founded and ran Clinically Vulnerable Awareness Day on 19 July, raising public understanding of the needs of Clinically Vulnerable people. It is also a founder member of World Ventil8 Day, the international awareness day for ventilation and indoor air quality, helping raise public awareness of the importance of clean indoor air for those at higher clinical risk. Improving accessibility of democratic participation. During the period the company carried out its first accessibility audit of polling stations, ahead of the May 2025 local elections, gathering evidence on the barriers Clinically Vulnerable people face in voting safely and sharing its findings with the Electoral Commission, which handles its engagement with the company through its partnership team. Through its own MyMaskMyVote initiative, run each year since 2023, the company raised public awareness of these accessibility barriers and of the measures - such as staff mask-wearing and ventilation - that help Clinically Vulnerable people vote safely. Peer support, information and safer access. Throughout the year the company provided peer support, information-sharing and practical guidance to help Clinically Vulnerable people and their families access healthcare, education and workplaces more safely, and to reduce the isolation experienced by many Clinically Vulnerable households. These activities were carried on for the benefit of the Clinically Vulnerable community across the United Kingdom and the wider public, and not for private gain.

The company's stakeholders are the Clinically Vulnerable people and households it exists to serve (who form its membership community), the wider public, and the organisations and institutions whose decisions affect this community, including the UK Covid-19 Inquiry. The company consulted its community through regular online meetings and by maintaining open lines of communication with members throughout the year, supplemented by surveys used to gather members' experiences. Feedback directly shaped the company's activities: the accounts and data gathered from the community informed the written and oral evidence submitted to the UK Covid-19 Inquiry, and members' priorities guided the company's awareness and information work.

During the period, one director received remuneration. The total remuneration paid to directors was £10,287.61. The director served without remuneration during the opening months of the period, and the amount paid represents a modest honorarium. All of the company's assets and surpluses continue to be applied for the benefit of the community in accordance with the asset lock. There were no other transactions or arrangements in connection with the remuneration of directors, or compensation for directors' loss of office, which require to be disclosed.

No transfer of assets other than for full consideration